Skip to search formSkip to main contentSkip to account menu

telavancin

Known as: Telavancina, Telavancinum, (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-{[(2S,3R,4S,5S,6R)-3-{[(2S,4S,5S,6S)-4-{[2-(decylamino)ethyl]amino}-5-hydroxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}-2 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (2)

AminoglycosidesAnti-Bacterial Agents
Bacterial InfectionsLipoglycopeptides [Chemical/Ingredient]telavancin 250 MG Injection [Vibativ]telavancin hydrochloride

Narrower (1)

TD 6424

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
BACKGROUND When hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is caused by gram-positive and gram… 
2012
2012
Comment on: Acute renal insufficiency during telavancin therapy in clinical practice.
Sir, The recent article by Marcos et al. raises serious concerns about the current dosing recommendations for telavancin. The… 
2011
2011
Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
Sir, With a rapid increase in invasive infections caused by methicillinresistant Staphylococcus aureus (MRSA), there is a demand… 
2009
2009
Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations
ABSTRACT We investigated the activity of telavancin, a novel lipoglycopeptide, alone and combined with gentamicin or rifampin… 
2009
2009
Comparative Efficacies of Telavancin and Vancomycin in Preventing Device-Associated Colonization and Infection by Staphylococcus aureus in Rabbits
ABSTRACT Telavancin is an investigational lipoglycopeptide antibiotic that is active against gram-positive pathogens. In an in… 
2008
2008
Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts)
Background Telavancin is a lipoglycopeptide with multiple mechanisms of action that include membrane-destabilizing effects… 
Review
2008
Review
2008
A new lipoglycopeptide: telavancin.
The increase in infections caused by resistant Gram-positive organisms has led to an urgent need for new antibiotics. Telavancin… 
2008
2008
Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
OBJECTIVES The aim of this study was to compare the pharmacodynamics of telavancin (TLV) and vancomycin (VAN) with Staphylococcus… 
2007
2007
Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus.
OBJECTIVES To assess the efficacy of telavancin, a rapidly bactericidal lipoglycopeptide, and three comparator agents in a murine… 
Review
2005
Review
2005
Telavancin (Theravance).
Theravance is developing telavancin, an injectable peptidoglycan inhibitor antibiotic for potential use in the treatment of Gram… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)